Moleculin Biotech, Inc. financial data

Symbol
MBRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
5300 Memorial Drive, Suite 950, Houston, TX
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 21, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 224 % -61.2%
Debt-to-equity 83.4 % +327%
Return On Equity -165 % -104%
Return On Assets -90 % -32.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14M shares +529%
Common Stock, Shares, Outstanding 3.38M shares +51.7%
Entity Public Float 9M USD -43.8%
Common Stock, Value, Issued 3K USD -90.9%
Weighted Average Number of Shares Outstanding, Basic 3.44M shares +74.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 17.7M USD -9.02%
General and Administrative Expense 8.79M USD -12.3%
Operating Income (Loss) -26.6M USD +10.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -21.8M USD +26.9%
Earnings Per Share, Basic -6.32 USD/shares +58.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.28M USD -81.8%
Assets, Current 5.19M USD -80.2%
Property, Plant and Equipment, Net 159K USD -41.5%
Operating Lease, Right-of-Use Asset 424K USD -19.1%
Assets 16.9M USD -55.7%
Accounts Payable, Current 2.03M USD -18.7%
Employee-related Liabilities, Current 1.82M USD +138%
Accrued Liabilities, Current 3.33M USD -22.9%
Liabilities, Current 5.36M USD -21.4%
Operating Lease, Liability, Noncurrent 358K USD -24.5%
Liabilities 10.9M USD -9.87%
Retained Earnings (Accumulated Deficit) -153M USD -16.5%
Stockholders' Equity Attributable to Parent 5.98M USD -77.1%
Liabilities and Equity 16.9M USD -55.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.72M USD -11.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 3.38M shares +51.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.73M USD -14.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.28M USD -81.8%
Deferred Tax Assets, Valuation Allowance 38.6M USD +19.6%
Deferred Tax Assets, Gross 38.7M USD +19.5%
Operating Lease, Liability 478K USD -16.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.8M USD +26.8%
Lessee, Operating Lease, Liability, to be Paid 566K USD -20.5%
Operating Lease, Liability, Current 120K USD +20%
Lessee, Operating Lease, Liability, to be Paid, Year Two 164K USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 159K USD +8.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 88K USD -36.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 141K USD -14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 339K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 61K USD -56.7%
Operating Lease, Payments 146K USD +8.96%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 126K USD -0.79%
Deferred Tax Assets, Net of Valuation Allowance 92K USD -17.9%
Share-based Payment Arrangement, Expense 1.73M USD -13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%